Marking a significant advancement in regenerative therapy for the treatment of ocular surface disease and disorders, BioTissue has unveiled CAM360 AmnioGraft (CAM360 AG), a new, hydrated, shelf-stable Cryopreserved Amniotic Membrane (CAM) solution that was developed to optimize comfort. The company has begun initial shipments of the product, with nationwide availability expected by the end of the month.
Ideal for patients who have mild to moderate dry eye disease and other ocular surface conditions, CAM360 AG is a ringless CAM that does not require refrigeration, making storage simple and convenient for all practices. Its adhesive properties1 ensure that the CAM stays in place under a Bandage Contact Lens (BCL), increasing patient comfort and treatment efficacy while patients go on with their normal daily lives.
“The introduction of CAM360 AG revolutionizes how eye care professionals can leverage regenerative medicine in the treatment of the ocular surface, particularly when it comes to dry eye disease,” said Ted Davis, President and CEO, BioTissue. “Dry eye disease is a progressive disease, and until now, the lack of options available meant that practitioners often had to wait until the patient’s condition worsened before they could intervene. CAM360 AG bridges that gap, enabling practitioners to provide more patients with treatment much earlier, which is a true reflection of our dedication to improving patients’ lives with everything we do.”
CAM products have been proven to alleviate signs and symptoms of dry eye disease, and its unique composition exerts potent anti-inflammatory, anti-scarring, and anti-angiogenic actions that help promote the body’s healing capabilities.2,3,4 It is adaptable to treat many conditions including mild to moderate dry eye disease, superficial punctate keratitis, neurotrophic keratitis, and more.
BioTissue’s proprietary CryoTek and SteriTek preservation methods are the only proven processing methods that retain the HC-HA/PTX3 found in fresh tissue, which is, in part, responsible for amniotic membrane’s therapeutic benefits.5 These processes were specifically designed to optimize preservation while providing efficiencies in handling, storage, and product application.
BioTissue has provided treatment to more than 800,000 patients, with its scientific and clinical breakthroughs documented in more than 390 peer-reviewed publications. The company remains at the forefront of innovation, actively conducting multiple clinical trials to obtain Biologic License Applications. These efforts address unmet needs in the ocular, orthopedic, and wound management markets, reaffirming BioTissue’s commitment to pioneering advancements in patient care.
For more information about BioTissue and CAM360 AG, visit BioTissue.com/ocular.
References
- BioTissue, Data on File, 2024
- John, T., Tighe, S., Sheha, H., Hamrah, P., Salem, Z. M., Cheng, A., ... & Rock, N. D.(2017). Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. Journal of Ophthalmology, 2017.
- McDonald, M. B., Sheha, H., Tighe, S., Janik, S. B., Bowden, F. W., Chokshi, A. R., ... & McMurren, B. J. (2018). Treatment outcomes in the dry eye amniotic membrane (DREAM) study. Clinical Ophthalmology, 677-681.
- Cheng, A. M., Zhao, D., Chen, R., Yin, H. Y., Tighe, S., Sheha, H., ... & Tseng, S. C.(2016). Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. The Ocular Surface, 14(1), 56-63.
- Cooke M, Tan EK, Mandrycky C, He H, O’Connell J, Tseng SC. J Wound Care. 2014;23(10):465-476.